RxDoctor Payments Data

Kathryn Doster, DO

Family Medicine · Santa Fe, NMNPI 1891358644

Payments from drug & device makers

$321in general payments, 2019–2025

Across 14 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Braeburn Inc.$109
  • Medtronic$51
  • Pfizer$48
  • Indivior Inc.$30
  • Astellas Pharma US Inc$22
  • Lilly USA, LLC$17
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$321100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$321 in reported general payments places this provider in the 65th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$325
Medicare patients
25
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$38,207
RybelsusSemaglutide18$35,861
JanuviaSitagliptin Phosphate19$28,160
MounjaroTirzepatide27$27,778
JardianceEmpagliflozin17$26,496
SublocadeBuprenorphine12$24,593
FarxigaDapagliflozin Propanediol20$21,456
EliquisApixaban11$16,926
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl31$6,705
Atrovent HfaIpratropium Bromide12$5,825
Arnuity ElliptaFluticasone Furoate16$4,551
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,156
Atorvastatin Calcium70$1,001
Gabapentin41$773
Albuterol Sulfate HfaAlbuterol Sulfate17$701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$12$28,16019 claims
Lilly USA, LLCMounjaro$17$27,77827 claims
Indivior Inc.Sublocade$30$24,59312 claims
PfizerEliquis$48$16,92611 claims
GSKArnuity Ellipta$16$4,55116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Santa Fe

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →